NASDAQ:KYTX
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. reported net income of −$161.3M in fiscal 2025. Free cash flow was −$153.7M, and the diluted share count rose 15.5%.Summary generated from Kyverna Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−64.7%
Debt / equityn/a
Free cash flow−$153.7M
FCF marginn/a
Share count change+15.5%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −62 | −143 | −170 |
| Net income | −60 | −127 | −161 |
| Free cash flow | −53 | −116 | −154 |
Recent filings
- 8-KRegulation FD disclosure
Sep 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 8-KEntry into a material agreement
Jul 27, 2026 - 8-KEntry into a material agreement
Jul 9, 2026 - 8-KResults of a shareholder vote
Jun 2, 2026 - 4Insider transaction report
May 29, 2026 - 4Insider transaction report
May 29, 2026